Item 1.01.Entry into A Material Definitive Agreement.

On June 24, 2022, Pacific Biosciences of California, Inc. ("PacBio") entered into an Amended and Restated Development and Commercialization Agreement (the "Amended and Restated Agreement") with Invitae Corporation ("Invitae"). The Amended and Restated Agreement amended and restated the existing Development and Commercialization Agreement, effective as of January 12, 2021, as amended by Amendment No. 1 to Development and Commercialization Agreement, entered into on June 3, 2021, by and between PacBio and Invitae (together, the "Original Agreement").

The parties anticipate that in connection with the Amended and Restated Agreement, PacBio will continue to receive feedback, input and insight from Invitae in connection with the intended development of its new sequencing systems; however, such feedback will not be contractually required and Invitae has no contractual right to participate in decisions regarding the development program for such new sequencing systems. PacBio's development plans for such new sequencing systems will be at PacBio's discretion and pursuant to its own internal processes and programs. Invitae will not be contractually obligated to reimburse PacBio for development costs under the Amended and Restated Agreement. In consideration of the non-refundable Development Costs (as defined in the Original Agreement) paid by Invitae to PacBio pursuant to the Original Agreement, PacBio will provide Invitae with credits and discounted pricing in connection with Invitae's anticipated purchase of currently available and in-development sequencing systems (instruments and consumables). In addition, subject to certain conditions, Invitae will be entitled to most favored pricing for the Company's Sequel IIe systems and certain in-development systems. There can be no assurances that the in-development sequencing systems will continue to be developed, be successfully developed or become available for commercial sale.

PacBio and Invitae each may terminate the Amended and Restated Agreement if the other party remains in material breach of the Amended and Restated Agreement following a cure period to remedy such breach.

The foregoing summary is not complete and is qualified in its entirety by reference to the Amended and Restated Agreement, which will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.




                                       ?

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses